RhumbLine Advisers’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-47,386
| Closed | -$277K | – | 3096 |
|
|
2019
Q1 | $277K | Buy |
47,386
+440
| +0.9% | +$1.5K | ﹤0.01% | 2586 |
|
|
2018
Q4 | $61K | Buy |
46,946
+13,660
| +41% | +$23.7K | ﹤0.01% | 2929 |
|
|
2018
Q3 | $115K | Sell |
33,286
-225
| -0.7% | -$845 | ﹤0.01% | 2848 |
|
|
2018
Q2 | $152K | Buy |
33,511
+7,648
| +30% | +$30.5K | ﹤0.01% | 2803 |
|
|
2018
Q1 | $85K | Buy |
25,863
+9,465
| +58% | +$33.5K | ﹤0.01% | 2765 |
|
|
2017
Q4 | $64K | Sell |
16,398
-3,471
| -17% | -$18.9K | ﹤0.01% | 2810 |
|
|
2017
Q3 | $206K | Buy |
19,869
+175
| +0.9% | +$1.72K | ﹤0.01% | 2718 |
|
|
2017
Q2 | $192K | Buy |
19,694
+6,896
| +54% | +$48.4K | ﹤0.01% | 2774 |
|
|
2017
Q1 | $87K | Buy |
12,798
+647
| +5% | +$3.74K | ﹤0.01% | 2788 |
|
|
2016
Q4 | $67K | Buy |
12,151
+1,652
| +16% | +$11.7K | ﹤0.01% | 2816 |
|
|
2016
Q3 | $80K | Buy |
10,499
+410
| +4% | +$3K | ﹤0.01% | 2831 |
|
|
2016
Q2 | $82K | Sell |
10,089
-327
| -3% | -$4.08K | ﹤0.01% | 2937 |
|
|
2016
Q1 | $135K | Hold |
10,416
| – | – | ﹤0.01% | 2842 |
|
|
2015
Q4 | $209K | Buy |
+10,416
| New | +$179K | ﹤0.01% | 2775 |
|
RhumbLine Advisers's IMDZ Position: Q2 2019 in Review
RhumbLine Advisers sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 47,386 shares — an estimated $277K sold.
RhumbLine Advisers first reported a position in IMDZ in Q4 2015 and held it in 14 quarters. The position peaked at $277K in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- RhumbLine Advisers reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- RhumbLine Advisers sold 47,386 Immune Design Corp. shares in Q2 2019, an estimated $277K.
- RhumbLine Advisers first reported a position in Immune Design Corp. in Q4 2015 and held it in 14 quarters.
- RhumbLine Advisers's Immune Design Corp. position peaked at $277K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.